Cartesian Therapeutics

Company snapshot

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com.

• 12 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 12 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Cartesian Therapeutics. Not investment advice.

• Peer + 0 momentum

  Karyopharm Therapeutics

  TA overlap score 36.4

• Peer + 0 momentum

  Nanjing Legend Biotech

  TA overlap score 27.2

Recent activity

Latest pipeline, patent, and corporate events for Cartesian Therapeutics.

1. Jun 8, 2026 Clinical update

   Descartes-08 — Phase 2

2. Jun 8, 2026 Clinical update

   Descartes-08 — Phase 2

3. Jun 8, 2026 Clinical update

   Descartes-08 — Phase 2

4. Jun 5, 2026 Clinical update

   Placebo to Descartes-08, Descartes-08 — Phase 3

5. Jun 5, 2026 Clinical update

   Descartes 30 — Phase 1

View all clinical trial activity →

• What is Cartesian Therapeutics?

  Cartesian Therapeutics is a pharma organization headquartered in Frederick, USA. It trades on NYSE under ticker RNAC. Primary therapeutic focus areas include Multiple Myeloma, generalized myasthenia gravis, Myasthaenia Gravis, Antisynthetase Syndrome, Childhood-onset Systemic Lup

• Is Cartesian Therapeutics publicly traded?

  Yes. Cartesian Therapeutics is listed with ticker RNAC on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Cartesian Therapeutics develop or market?

  We link 4 drug profile(s) where Cartesian Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cartesian-therapeutics#company-drugs.

• What are the latest developments for Cartesian Therapeutics?

  In the last 12 months our linked public records show 12 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Cartesian Therapeutics focus on?

  Cartesian Therapeutics focuses on Multiple Myeloma, generalized myasthenia gravis, Myasthaenia Gravis based on our analysis of their pipeline programs and drug development activities.